3
|
Chen Y, Zhao Y, Chen J, Peng C, Zhang Y, Tong R, Cheng Q, Yang B, Feng X, Lu Y, Xie H, Zhou L, Wu J, Zheng S. ALKBH5 suppresses malignancy of hepatocellular carcinoma via m 6A-guided epigenetic inhibition of LYPD1. Mol Cancer 2020; 19:123. [PMID: 32772918 PMCID: PMC7416417 DOI: 10.1186/s12943-020-01239-w] [Citation(s) in RCA: 160] [Impact Index Per Article: 40.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/10/2020] [Accepted: 07/31/2020] [Indexed: 02/06/2023] Open
Abstract
Background N6-methyladenosine (m6A) modification is an emerging layer of epigenetic regulation which is widely implicated in the tumorigenicity of hepatocellular carcinoma (HCC), offering a novel perspective for investigating molecular pathogenesis of this disease. The role of AlkB homolog 5 (ALKBH5), one of the m6A demethylases, has not been fully explored in HCC. Here we clarify the biological profile and potential mechanisms of ALKBH5 in HCC. Methods Expression of ALKBH5 and its correlation with clinicopathological characteristics of HCC were evaluated using tissue microarrays and online datasets. And biological effects of ALKBH5 in HCC were determined in vitro and in vivo. Subsequently, methylated RNA immunoprecipitation sequencing (MeRIP-seq) combined with RNA sequencing (RNA-seq), and following m6A dot blot, MeRIP-qPCR, RIP-qPCR or dual luciferase reporter assays were employed to screen and validate the candidate targets of ALKBH5. Results We demonstrated that ALKBH5 was down-regulated in HCC, and decreased ALKBH5 expression was an independent prognostic factor of worse survival in HCC patients. Functionally, ALKBH5 suppressed the proliferation and invasion capabilities of HCC cells in vitro and in vivo. Mechanistically, ALKBH5-mediated m6A demethylation led to a post-transcriptional inhibition of LY6/PLAUR Domain Containing 1 (LYPD1), which could be recognized and stabilized by the m6A effector IGF2BP1. In addition, we identified that LYPD1 induced oncogenic behaviors of tumors in contrast to ALKBH5. Dysregulation of ALKBH5/LYPD1 axis impelled the progression of HCC. Conclusion Our study reveals that ALKBH5, characterized as a tumor suppressor, attenuates the expression of LYPD1 via an m6A-dependent manner in HCC cells. Our findings enrich the landscape of m6A-modulated tumor malignancy, and provide new insights into potential biomarkers and therapeutic targets of HCC treatment.
Collapse
Affiliation(s)
- Yunhao Chen
- Division of Hepatobiliary and Pancreatic Surgery, Department of Surgery, First Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, 310003, China.,NHC Key Laboratory of Combined Multi-organ Transplantation, Hangzhou, 310003, China.,Key Laboratory of the diagnosis and treatment of organ Transplantation, CAMS, Hangzhou, 310003, China.,Key Laboratory of Organ Transplantation, Hangzhou, 310003, Zhejiang Province, China
| | - Yanchun Zhao
- Hematology Department, the First Affiliated Hospital of Medical School of Zhejiang University, Hangzhou, 310003, China
| | - Junru Chen
- Division of Hepatobiliary and Pancreatic Surgery, Department of Surgery, First Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, 310003, China.,NHC Key Laboratory of Combined Multi-organ Transplantation, Hangzhou, 310003, China
| | - Chuanhui Peng
- Division of Hepatobiliary and Pancreatic Surgery, Department of Surgery, First Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, 310003, China.,Key Laboratory of the diagnosis and treatment of organ Transplantation, CAMS, Hangzhou, 310003, China.,Zhejiang Provincial Research Center for Diagnosis and Treatment of Hepatobiliary Diseases (JBZX-202004), Hangzhou, 310003, China
| | - Yanpeng Zhang
- NHC Key Laboratory of Combined Multi-organ Transplantation, Hangzhou, 310003, China.,Key Laboratory of Organ Transplantation, Hangzhou, 310003, Zhejiang Province, China
| | - Rongliang Tong
- Division of Hepatobiliary and Pancreatic Surgery, Department of Surgery, First Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, 310003, China.,Key Laboratory of the diagnosis and treatment of organ Transplantation, CAMS, Hangzhou, 310003, China.,Zhejiang Provincial Research Center for Diagnosis and Treatment of Hepatobiliary Diseases (JBZX-202004), Hangzhou, 310003, China
| | - Qiyang Cheng
- NHC Key Laboratory of Combined Multi-organ Transplantation, Hangzhou, 310003, China.,Key Laboratory of Organ Transplantation, Hangzhou, 310003, Zhejiang Province, China
| | - Beng Yang
- NHC Key Laboratory of Combined Multi-organ Transplantation, Hangzhou, 310003, China.,Key Laboratory of Organ Transplantation, Hangzhou, 310003, Zhejiang Province, China
| | - Xiaode Feng
- NHC Key Laboratory of Combined Multi-organ Transplantation, Hangzhou, 310003, China.,Key Laboratory of Organ Transplantation, Hangzhou, 310003, Zhejiang Province, China
| | - Yuejie Lu
- NHC Key Laboratory of Combined Multi-organ Transplantation, Hangzhou, 310003, China.,Key Laboratory of Organ Transplantation, Hangzhou, 310003, Zhejiang Province, China
| | - Haiyang Xie
- Division of Hepatobiliary and Pancreatic Surgery, Department of Surgery, First Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, 310003, China.,NHC Key Laboratory of Combined Multi-organ Transplantation, Hangzhou, 310003, China.,Key Laboratory of the diagnosis and treatment of organ Transplantation, CAMS, Hangzhou, 310003, China.,Key Laboratory of Organ Transplantation, Hangzhou, 310003, Zhejiang Province, China
| | - Lin Zhou
- Division of Hepatobiliary and Pancreatic Surgery, Department of Surgery, First Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, 310003, China.,NHC Key Laboratory of Combined Multi-organ Transplantation, Hangzhou, 310003, China.,Key Laboratory of the diagnosis and treatment of organ Transplantation, CAMS, Hangzhou, 310003, China.,Key Laboratory of Organ Transplantation, Hangzhou, 310003, Zhejiang Province, China
| | - Jian Wu
- Division of Hepatobiliary and Pancreatic Surgery, Department of Surgery, First Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, 310003, China. .,Key Laboratory of the diagnosis and treatment of organ Transplantation, CAMS, Hangzhou, 310003, China. .,Zhejiang Provincial Research Center for Diagnosis and Treatment of Hepatobiliary Diseases (JBZX-202004), Hangzhou, 310003, China.
| | - Shusen Zheng
- Division of Hepatobiliary and Pancreatic Surgery, Department of Surgery, First Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, 310003, China. .,NHC Key Laboratory of Combined Multi-organ Transplantation, Hangzhou, 310003, China. .,Key Laboratory of the diagnosis and treatment of organ Transplantation, CAMS, Hangzhou, 310003, China. .,Key Laboratory of Organ Transplantation, Hangzhou, 310003, Zhejiang Province, China. .,Zhejiang Provincial Research Center for Diagnosis and Treatment of Hepatobiliary Diseases (JBZX-202004), Hangzhou, 310003, China.
| |
Collapse
|
5
|
Jadkauskaite L, Coulombe PA, Schäfer M, Dinkova-Kostova AT, Paus R, Haslam IS. Oxidative stress management in the hair follicle: Could targeting NRF2 counter age-related hair disorders and beyond? Bioessays 2017; 39. [PMID: 28685843 DOI: 10.1002/bies.201700029] [Citation(s) in RCA: 28] [Impact Index Per Article: 4.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/05/2023]
Abstract
Widespread expression of the transcription factor, nuclear factor (erythroid-derived 2)-like 2 (NRF2), which maintains redox homeostasis, has recently been identified in the hair follicle (HF). Small molecule activators of NRF2 may therefore be useful in the management of HF pathologies associated with redox imbalance, ranging from HF greying and HF ageing via androgenetic alopecia and alopecia areata to chemotherapy-induced hair loss. Indeed, NRF2 activation has been shown to prevent peroxide-induced hair growth inhibition. Multiple parameters can increase the levels of reactive oxygen species in the HF, for example melanogenesis, depilation-induced trauma, neurogenic and autoimmune inflammation, toxic drugs, environmental stressors such as UV irradiation, genetic defects and aging-associated mitochondrial dysfunction. In this review, the potential mechanisms whereby NRF2 activation could prove beneficial in treatment of redox-associated HF disorders are therefore discussed.
Collapse
Affiliation(s)
- Laura Jadkauskaite
- Centre for Dermatology Research, School of Biological Sciences, University of Manchester, Manchester, UK
| | - Pierre A Coulombe
- Department of Biochemistry and Molecular Biology, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA
| | - Matthias Schäfer
- Department of Biology, Institute of Molecular Health Sciences, Swiss Institute of Technology (ETH), Zürich, Switzerland
| | - Albena T Dinkova-Kostova
- Division of Cancer Research, School of Medicine, Jacqui Wood Cancer Centre, Ninewells Hospital and Medical School, University of Dundee, Dundee, UK
| | - Ralf Paus
- Centre for Dermatology Research, School of Biological Sciences, University of Manchester, Manchester, UK.,Department of Dermatology, University of Münster, Münster, Germany
| | - Iain S Haslam
- Centre for Dermatology Research, School of Biological Sciences, University of Manchester, Manchester, UK.,Department of Biological Sciences, School of Applied Science, University of Huddersfield, Huddersfield, UK
| |
Collapse
|
11
|
Ke N, Sundaram R, Liu G, Chionis J, Fan W, Rogers C, Awad T, Grifman M, Yu D, Wong-Staal F, Li QX. Orphan G protein-coupled receptor GPR56 plays a role in cell transformation and tumorigenesis involving the cell adhesion pathway. Mol Cancer Ther 2007; 6:1840-50. [PMID: 17575113 DOI: 10.1158/1535-7163.mct-07-0066] [Citation(s) in RCA: 50] [Impact Index Per Article: 2.9] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/22/2022]
Abstract
GPR56 is an orphan G protein - coupled receptor, mutations of which have recently been associated with bilateral frontoparietal polymicrogyria, a rare neurologic disease that has implications in brain development. However, no phenotype beyond central nervous system has yet been described for the GPR56-null mutations despite abundant GPR56 expression in many non - central nervous system adult tissues. In the present study, we show that higher GPR56 expression is correlated with the cellular transformation phenotypes of several cancer tissues compared with their normal counterparts, implying a potential oncogenic function. RNA interference-mediated GPR56 silencing results in apoptosis induction and reduced anchorage-independent growth of cancer cells via increased anoikis, whereas cDNA overexpression resulted in increased foci formation in mouse fibroblast NIH3T3 cell line. When GPR56 silencing was induced in vivo in several xenograft tumor models, significant tumor responses (including regression) were observed, suggesting the potential of targeting GPR56 in the development of tumor therapies. The expression profiling of GPR56-silenced A2058 melanoma cell line revealed several genes whose expression was affected by GPR56 silencing, particularly those in the integrin-mediated signaling and cell adhesion pathways. The potential role of GPR56 in cancer cell adhesion was further confirmed by the observation that GPR56 silencing also reduced cell adhesion to the extracellular matrix, which is consistent with the observed increase in anoikis and reduction in anchorage-independent growth phenotypes. The oncogenic potential and apparent absence of physiologic defects in adult human tissues lacking GPR56, as well as the targetable nature of G protein - coupled receptor by small molecule or antibody, make GPR56 an attractive drug target for the development of cancer therapies.
Collapse
Affiliation(s)
- Ning Ke
- Immusol, Inc., San Diego, CA 92121, USA
| | | | | | | | | | | | | | | | | | | | | |
Collapse
|